2021 | Real-world evidence on the strategy of olmesartan-based triple single-pill combination in Korean hypertensive patients: a prospective, multicenter, observational study (RESOLVE-PRO)
| Clinical Hypertension |
2021 | Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
| TRANSLATIONAL LUNG CANCER RESEARCH |
2022 | Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effect
| SCIENTIFIC REPORTS |
2022 | Real-World Experience of Long-Term Dupilumab Treatment for Atopic Dermatitis in Korea
| ANNALS OF DERMATOLOGY |
2020 | Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
| CANCER RESEARCH AND TREATMENT |
2019 | Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study
| JOURNAL OF CLINICAL MEDICINE |
2022 | Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea | GYNECOLOGIC ONCOLOGY |
2020 | Real-World Experience of Pembrolizumab Monotherapy in Patients with Recurrent or Persistent Cervical Cancer: A Korean Multi-Center Retrospective Study (KGOG1041)
| CANCERS |
2022 | Real-world experience of safety and effectiveness of regorafenib for treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and hepatocellular carcinoma: a post-marketing surveillance study in Korea
| JOURNAL OF CANCER |
2023 | Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data
| TRANSLATIONAL LUNG CANCER RESEARCH |
2022 | Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
2023 | Real-world impact of the fixed-dose combination on improving treatment outcomes of drug-susceptible tuberculosis: a comparative study using multiyear national tuberculosis patient data
| BMJ OPEN RESPIRATORY RESEARCH |
2021 | Real-world incidence of endopthalmitis after intravitreal anti-VEGF injections in Korea: findings from the Common Data Model in ophthalmology
| EPIDEMIOLOGY AND HEALTH |
2021 | Real-World Long-Term Clinical Outcomes of Ultrathin Strut Biodegradable Polymer Drug-Eluting Stents in Korean ST-Segment-Elevation Myocardial Infarction (STEMI) Patients with or without Acute Heart Failure Undergoing Primary Percutaneous Coronary Intervention
| JOURNAL OF CLINICAL MEDICINE |
2020 | Real-World National Colonoscopy Volume in Korea: A Nationwide Population-Based Study over 12 Years
| Gut and Liver |
2021 | Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05 | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
2021 | Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis | CANCER COMMUNICATIONS |
2020 | Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study | TARGETED ONCOLOGY |
2024 | Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)
| BMC CANCER |
2022 | Real-world practice patterns and characteristics of adverse events with selexipag in Korean patients with pulmonary arterial hypertension | EXPERT OPINION ON DRUG SAFETY |